sodium benzoate (EX039)
/ Excelsior
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 27, 2025
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Excelsior | Trial primary completion date: Aug 2025 ➔ Dec 2026
Trial primary completion date • Alzheimer's Disease • CNS Disorders
September 08, 2023
A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Excelsior | Trial completion date: Nov 2024 ➔ Feb 2027 | Trial primary completion date: Aug 2024 ➔ Aug 2025
Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders
February 15, 2023
A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Excelsior | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders
June 10, 2022
A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Excelsior
New P2 trial • Alzheimer's Disease • CNS Disorders
1 to 4
Of
4
Go to page
1